Immunohistochemical analysis of CYP2A13 in various types of human lung cancers by Fukami Tatsuki et al.
Immunohistochemical analysis of CYP2A13 in
various types of human lung cancers
著者 Fukami Tatsuki, Nakajima Miki, Matsumoto Isao,










Immunohistochemical analysis of CYP2A13 in various
types of human lung cancers
Tatsuki Fukami,1 Miki Nakajima,1,4 Isao Matsumoto,2 Yoh Zen,3 Makoto Oda2 and Tsuyoshi Yokoi1
1Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa; 2Department of General and
Cardiothoracic Surgery, Kanazawa University School of Medicine, Takara-machi, Kanazawa; 3Division of Pathology, Kanazawa University Hospital,
Takara-machi, Kanazawa, Japan
(Received September 8, 2009 ⁄ Revised December 11, 2009 ⁄Accepted December 18, 2009 ⁄Online publication February 22, 2010)4To whom correspondence should be addressed.
E-mail: nmiki@kenroku.kanazawa-u.ac.jpHuman CYP2A13, which is expressed in the respiratory tract, is the
most efficient enzyme for the metabolic activation of tobacco-spe-
cific nitrosamines such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK). The relevance of CYP2A13 in carcinogenicity and
toxicity in the respiratory tract has been suggested, but the
expression of CYP2A13 protein in lung cancer tissues remains to
be determined. We first prepared a mouse monoclonal antibody
against human CYP2A13. The antibody showed no cross reactivity
with the other CYP isoforms including CYP2A6. Using the specific
antibody, we performed immunohistochemical analysis for human
lung carcinomas. In adenocarcinomas (n = 15), all specimens were
positive for the staining and five samples showed strong staining.
In squamous cell carcinomas (n = 15) and large cell carcinomas
(n = 15), each 14 samples were positive for the staining and two
and three samples showed strong staining, respectively. In small
cell carcinoma samples (n = 15), eight samples were negative for
the staining and five samples showed weak or moderate staining.
In conclusion, we first found that the expression of CYP2A13 was
markedly increased in non-small cell lung carcinomas. The high
expression might be associated with the tumor development and
progression in non-small cell lung carcinomas. (Cancer Sci 2010;
101: 1024–1028)
T he human cytochrome P450 2A (CYP2A) subfamily com-prises three members: CYP2A6, CYP2A7, and
CYP2A13.(1) Among them, CYP2A6 and CYP2A13 are func-
tional enzymes.(2,3) They are composed of 494 amino acids with
a high degree of identity (93.5%). It has been reported that
CYP2A6 is expressed in liver, whereas CYP2A13 is predomi-
nantly expressed in the respiratory tract, with the highest level
in the nasal mucosa, followed by the lung and trachea.(3–5) The
expression has been analyzed at the mRNA level. The tissue dis-
tribution of CYP2A13 at the protein level has not been deter-
mined because a specific antibody against CYP2A13 is not
commercially available.
CYP2A13 is the most efficient enzyme in the metabolism of
nicotine and cotinine as well as the metabolic activation of 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) with sim-
ilar substrate specificity as CYP2A6.(3,6) Recently, we found that
CYP2A13 efficiently metabolizes various environmental chemi-
cals in air pollutants or tobacco smoke such as 4-aminobiphenyl,
naphthalene, styrene, and toluene.(7,8) Since these chemicals are
easily absorbed by inhalation, CYP2A13 in the lung plays an
important role in the local metabolism of the chemicals. It is
considered that CYP2A13 would be relevant to carcinogenicity
and toxicity in the lung.
The human P450 isoforms of which the expression in lung
cancer has been most studied are CYP1A1 and CYP1B1,
because cigarette smoking containing polycyclic aromatic
hydrocarbons induces their expression.(9) Especially, CYP1B1 is
highly expressed in lung non-small cell carcinomas compared
with normal tissues.(10,11) CYP1A1 and CYP1B1 catalyze theCancer Sci | April 2010 | vol. 101 | no. 4 | 1024–1028metabolic activation of polycyclic aromatic hydrocarbons,
which would be one of the causal factors of lung cancer. Since
CYP2A13 is involved in the metabolic activation of environ-
mental chemicals, it is important to know the expression level of
CYP2A13 protein in lung cancer. Previously, Zhu et al. reported
that CYP2A13 protein could not be detected in lung cancers by
immunohistochemical analysis using a polyclonal antibody they
made.(12) In the present study, we originally prepared an anti-
body against CYP2A13. Using the antibody, we evaluated the
expression of CYP2A13 protein in various types of human lung
cancers.
Materials and Methods
Chemicals and reagents. Normal mouse IgG and biotinylated
goat anti-mouse IgG were obtained from Santa Cruz biotechnol-
ogy (Santa Cruz, CA, USA) and Zymed (South San Francisco,
CA, USA), respectively. Mayer’s hematoxylin solution was
purchased from Wako Pure Chemical Industries (Osaka, Japan).
Recombinant human P450 enzymes. Recombinant human
CYP1A1, CYP1B1, CYP2B6, CYP2D6, CYP2E1, and CYP3A4
expressed in baculovirus-infected insect cells (Supersomes)
were purchased from BD Gentest (Woburn, MA, USA). E. coli
membranes expressing human CYP2A6 and CYP2A13 were
previously prepared.(13,14) The expression system of human
CYP2S1 in E. coli was constructed according to the method by
Wu et al.(15) and E. coli membranes expressing CYP2S1 were
also prepared. The P450 content and protein concentration were
determined according to the method described previously.(13)
Preparation of antibody against CYP2A13. Recombinant
human CYP2A13 expressed in E. coli was purified according to
the method described previously.(16) Mouse monoclonal anti-
body against human CYP2A13 was prepared by Kohjin Bio
(Saitama, Japan). The hybridomas producing the antibodies
were screened by ELISA with the purified recombinant
CYP2A13 and CYP2A6. The clones reacted with CYP2A13,
but not with CYP2A6 were selected. Among them, a clone
showing highest reactivity was expanded by intraperitoneal
injection into mineral oil-primed mice. Monoclonal antibodies
from mouse ascitic fluids were partially purified by precipitation
with 33% ammonium sulfate. Finally, the specificity of the anti-
body was confirmed by immunoblot analysis as described
below.
Immunoblot analysis. SDS-polyacrylamide gel electrophore-
sis and immunoblot analysis were performed according to Lae-
mmli.(17) The recombinant CYP1A1, CYP1B1, CYP2A6,
CYP2A13, CYP2B6, CYP2D6, CYP2E1, CYP2S1, and
CYP3A4 (each 1 pmol) were separated on 10% polyacrylamide
gel and transferred electrophoretically to a polyvinylidene diflu-
oride membrane, Immobilon-P (Millipore, Billerica, MA, USA).doi: 10.1111/j.1349-7006.2010.01482.x
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Fig. 1. Immunoblot analysis using the mouse monoclonal antibody
against human CYP2A13 prepared in this study. One pmol each of
recombinant P450 isoforms, CYP1A1, CYP1B1, CYP2B6, CYP2D6,
CYP2E1, and CYP3A4 expressed in baculovirus-infected insect cells and
CYP2A6, CYP2A13, and CYP2S1 expressed in E. coli, were separated on
10% SDS-PAGE.The membrane was blocked in 3% non-fat dry milk in phos-
phate-buffered saline (PBS) containing 0.1% Tween 20 for 12 h
at room temperature. The membranes were incubated with the
prepared mouse monoclonal anti-CYP2A13 antibody (1:2000,
PBS) for 1 h at room temperature. Biotinylated anti-mouse IgG
and the VECTASTAIN ABC kit (Vector Laboratories, Burlin-
game, CA, USA) were used for diaminobenzidine staining.
Tissue samples. Fifteen specimens each of adenocarcinoma,
squamous cell carcinoma, large cell carcinoma, and small cell
carcinoma obtained from surgically removed lung tissues
were used. These specimens were collected between 1997 and
2005 at the Pathology Departments of Kanazawa University
Hospital, Japan. The age and sex of the patients were as fol-
lows: adenocarcinomas, 44–75 years, 10 men and five women;
squamous cell carcinomas, 36–83 years, 12 men and three
women; large cell carcinomas, 36–80 years, 14 men and one
woman; small cell carcinomas, 56–83 years, 14 men and
one woman. These specimens were fixed in neutral formalin and
then embedded in paraffin for immunohistochemistry. This
study was approved by the Ethics Committee of Kanazawa
University (Kanazawa, Japan).
Immunohistochemistry. The sections described above were
first deparaffinized with xylene three times for 5 min each and
hydrated gradually through a series of graded ethanol (100%,
99.5%, 90%, 70%). After the washes with distilled water for
5 min, the sections were treated with a liberated antibody bind-
ing solution (Polysciences, Warrington, PA, USA) for 8 min to
liberate the antigen-epitope site. Endogenous peroxidase activity
in the sections was blocked with 3% hydrogen peroxide in PBS
for 30 min. Nonspecific binding was blocked with 1.5% normal
rabbit serum for 30 min at room temperature. The sections were
then incubated with the mouse monoclonal anti-CYP2A13 anti-
body at 4C for 16 h. The sections were then rinsed in PBS for
5 min and incubated with biotinylated goat anti-mouse IgG as
the second antibody for 30 min at room temperature. After rins-
ing with PBS, staining reactions were performed using the
ABC-elite kit. After counterstaining with Mayer’s hematoxylin
solution, the sections were mounted. As a negative control, nor-
mal mouse IgG was used instead of the anti-CYP2A13 antibody.
The staining intensity of tumor cells was estimated as follows:
0, no staining; 1, weakly staining; 2, moderately staining; 3,
strongly staining. The estimated percentages of positive tumor
cells were classified as follows: 0, none; 1, <10%; 2, 10–50%; 3,
>50%. The products of the scores 0–1, 2–4, 6–9 were defined as
), +, ++, and +++, respectively.
Statistical analyses. The statistical significance of differences
in the extent of staining between different types of lung carci-
noma was tested by Fisher’s exact method. A value of P < 0.05
was considered statistically significant.
Results
Specificity of the anti-human CYP2A13 antibody. The speci-
ficity of the raised monoclonal antibody against human
CYP2A13 was evaluated with immunoblot analysis. A panel of
recombinant CYP isoforms, CYP1A1, CYP1B1, CYP2B6,
CYP2D6, CYP2E1, and CYP3A4 expressed in baculovirus-
infected insect cells as well as CYP2A6, CYP2A13, and
CYP2S1 expressed in E. coli membrane, were separated on
SDS-PAGE (Fig. 1). The antibody prepared in this study specifi-
cally reacted with CYP2A13. It did not react with the other
P450 isoforms including CYP2A6.
Immunohistochemical analysis of CYP2A13 for human lung
cancer. The antibody was used for the immunohistochemical
analysis of a total of 60 lung cancer tissues. In adjacent noncan-
cerous tissues, strong staining was observed in the epithelial
cells of the bronchus (Fig. 2a), but no staining was observed in
peripheral lung tissues (Fig. 2b). We confirmed the absence ofFukami et al.staining in human liver (data not shown), supporting the speci-
ficity of this antibody. Next, we evaluated the staining of differ-
ent types of lung carcinoma (Fig. 2c–f). All of 15
adenocarcinomas showed positive immunostaining, and five and
three samples were judged as +++ and ++, respectively
(Table 1). Each 14 samples of 15 squamous cell carcinomas and
15 large cell carcinomas were positive for the staining, and eight
squamous cell carcinomas and six large cell carcinomas were
judged as +++ or ++. In contrast, in 15 small cell carcinomas,
eight samples were negative for the staining and five samples
were judged as + or ++. These results suggest that CYP2A13 is
highly expressed in non-small cell carcinomas.
Relationship between the CYP2A13 levels and smoking status
or clinical characteristics of lung cancer. The relationship
between the CYP2A13 staining levels and smoking status was
evaluated (Table 2). In 15 adenocarcinomas and 15 squamous cell
carcinomas, 10 and 12 samples were smokers, respectively. All of
15 large cell carcinomas and small cell carcinomas were smokers.
No relationship was observed between the CYP2A13 immuno-
staining levels and the pack-years. We also investigated the rela-
tionship between the CYP2A13 staining levels and the extents of
the primary tumor (T-factor), regional lymph node metastasis
(N-factor), and distant metastasis (M-factor), and the clinical
stage was also evaluated (Table 2). In adenocarcinomas, squa-
mous cell carcinomas, and large cell carcinomas, no relationship
was observed. In small cell carcinomas, significant differences
were observed in the extent of CYP2A13 staining with the values
of N-factor and the clinical stage. However, we could not draw
definitive conclusions because of the limited number of samples.
Discussion
In previous studies, the tissue distribution of CYP2A13 was ana-
lyzed at the mRNA level, demonstrating the expression in the
respiratory tract including the nasal mucosa, trachea, and
lung.(3–5) Recently, Wong et al. successfully detected CYP2A13
protein in fetal nasal microsomes by immunoblotting using a
polyclonal anti-mouse Cyp2a5 antibody.(18) Although this anti-
body reacted with CYP2A6, they could separate CYP2A13 from
CYP2A6 by high resolution SDS-PAGE using a DNA sequenc-
ing apparatus. Zhang et al. detected CYP2A13 protein in lung
microsomes by immunoblotting using the anti-Cyp2a5 antibody,
in which immunoprecipitants from lung microsomes using the
anti-Cyp2a5 antibody were separated.(19) Thus, since a specific
antibody to CYP2A13 has not been available, great effort has
been required to detect CYP2A13 protein. This background
prompted us to prepare a specific antibody against human
CYP2A13.
The amino acid identities of CYP2A13 with CYP2A6,
CYP2B6, and CYP2S1 are 93.5%, 53.4%, and 47.5%, respec-
tively. It has been demonstrated that a monoclonal antibody
against CYP2A6 from BD Gentest reacts with not only CYP2A6
but also CYP2A13 and CYP2E1.(12) It seems that anti-rat
CYP2A antibody reacted with CYP2S1 protein in human hepa-
tic stellate cells.(20) We investigated whether our antibodyCancer Sci | April 2010 | vol. 101 | no. 4 | 1025
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Table 1. CYP2A13-specific staining in lung adenocarcinoma,




) + ++ +++
Adenocarcinoma (n = 15) 0 7 3 5
Squamous cell carcinoma (n = 15) 1 6 6 2
Large cell carcinoma (n = 15) 1 8 3 3
Small cell carcinoma (n = 15) 8 4 1 2
The statistical significance of differences in the extent of staining in
the different lung carcinoma types was tested by Fisher’s exact
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Fig. 2. Immunohistochemical analysis of CYP2A13
in human lung cancer tissues. Adjacent
noncancerous (a) bronchus and (b) peripheral lung
tissues; (c) adenocarcinoma; (d) squamous cell
carcinoma; (e) large cell carcinoma; (f) small cell
carcinoma. Strong immunostaining was observed in
the epithelial cells in bronchus, but not in
peripheral lung tissues. In lung carcinomas,
immunostaining was positive in most of non-small
cell carcinomas. In contrast, the staining was mostly
negative in small cell carcinoma. Original mag-
nification, ·200.against CYP2A13 may react with other P450 isoforms including
CYP2A6, CYP2B6, and CYP2S1. In the results, it was demon-
strated that the antibody specifically reacted with CYP2A13
(Fig. 1). Thus, we succeeded in preparing an antibody specific
to human CYP2A13.
Using the specific antibody against CYP2A13, we performed
immunoblot analysis using human normal lung microsomes, but
we observed no band (data not shown). Then, we performed
immunohistochemical analysis using lung cancer tissues. In
adjacent noncancerous tissues, strong staining was observed in
the epithelial cells of the bronchus, but no staining was observed1026in peripheral lung tissues (Fig. 2a,b). Thus, the expression of
CYP2A13 is not uniform in the lung, supporting the negative
results of the immunoblot analysis using microsomes prepared
from whole lung tissues. The distribution of CYP2A13 in the
epithelial cells of the bronchus would be physiologically reason-
able, because CYP2A13 plays a role in the metabolism of envi-
ronmental chemicals. When four kinds of lung carcinomas were
evaluated for the CYP2A13 expression, we found differences in
the extent of the immunostaining. The strong staining was
observed in most samples of non-small cell carcinomas. In gen-
eral, it is well known that squamous cell carcinoma and small
cell carcinoma are associated with tobacco smoking.(21,22) Ade-
nocarcinoma is the most common type of lung cancer in female
nonsmokers, and it is increasingly associated with smoking as
well. In contrast, no association has been reported for large cell
carcinoma with smoking.(23) Recently, we found that CYP2A13
metabolically activates 4-aminobiphenyl, naphthalene, and sty-
rene which are carcinogenic components in tobacco smoke.(7,8)
CYP2A13 metabolically activates NNK, a causal factor of lung
adenocarcinoma.(24) In support, there are studies showing a rela-
tionship between the genetic polymorphism of the CYP2A13
gene and the risk of lung adenocarcinoma.(25,26) Thus, higher
expression of CYP2A13 in adenocarcinoma and squamous cell
carcinoma may be associated with the tumor development and
progression. However, we have no conclusive explanation for
low expression of CYP2A13 in small cell carcinoma. The regu-
lation mechanism of CYP2A13 may be different in differentdoi: 10.1111/j.1349-7006.2010.01482.x
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Table 2. Characteristics of patients with lung adenocarcinoma, squamous cell carcinoma, large cell carcinoma, or small cell carcinoma in
relation to expression level of CYP2A13
Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Small cell carcinoma
) + ++ +++ P ) + ++ +++ P ) + ++ +++ P ) + ++ +++ P
Smoking status
Never smokers 0 2 1 2 1.000 1 1 1 0 0.446 0 0 0 0 1.000 0 0 0 0 1.000
Smokers 0 5 2 3 0 5 5 2 1 8 3 3 8 4 1 2
Pack-years
<35 4 2 3 1.000 1 2 0 1.000 0 2 0 2 0.351 3 0 0 0 0.434
35–64 0 0 0 2 1 1 1 5 1 1 3 3 0 1
65–94 1 0 0 1 0 0 0 1 2 0 1 1 1 0
95< 0 0 0 1 2 1 0 0 0 0 1 0 0 1
T-factor
1 0 2 1 3 0.670 1 2 1 1 0.914 0 1 0 1 0.990 4 4 0 0 0.119
2 0 4 1 1 0 1 2 1 0 3 1 0 3 0 1 2
3 0 0 1 1 0 2 3 0 1 2 1 1 0 0 0 0
4 0 1 0 0 0 1 0 0 0 2 1 1 1 0 0 0
N-factor
0 0 3 2 5 0.400 0 4 5 1 0.188 1 4 1 1 1.000 6 0 0 0 0.004
1 0 2 1 0 1 0 0 1 0 1 0 1 0 1 0 2
2 0 2 0 0 0 2 1 0 0 3 2 1 2 3 1 0
3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
M-factor
0 0 6 2 5 0.667 1 5 6 2 1.000 1 8 3 3 1.000 8 4 1 2 1.000
1 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0
Clinical Stage
IA 0 1 1 3 0.908 0 1 1 1 0.752 0 1 0 1 1.000 3 0 0 0 0.052
IB 0 2 0 1 0 0 1 0 0 1 0 0 2 0 0 0
IIA 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0
IIB 0 1 1 1 0 1 3 1 1 3 1 1 0 0 0 2
IIIA 0 0 0 0 0 2 1 0 0 1 1 0 2 3 1 0
IIIB 0 1 0 0 0 1 0 0 0 2 1 0 1 0 0 0
IV 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0
I 0 3 1 4 0.907 0 1 2 1 0.717 0 2 0 1 0.930 5 0 0 0 0.012
II 0 2 1 1 1 1 3 1 1 3 1 1 0 1 0 2
III 0 1 0 0 0 3 1 0 0 3 2 0 3 3 1 0
IV 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0cancer types. Furthermore, we cannot speculate the reason at the
present why the cancer cells still need the function protein of
CYP2A13 after carcinogenic events. Clarifying this issue would
contribute to our understanding for physiological and biological
significance of CYP2A13.
While performing this study, another research group also gen-
erated a specific antibody against CYP2A13.(12) In contrast to
our study, they used a synthetic peptide covering C-terminal
amino acid residues 369 to 377 as an antigen. They confirmed
that the antibody reacted with CYP2A13 but not with CYP2A6,
CYP2S1, CYP3A4, and mouse CYP2A5 by immunoblot analy-
sis using recombinant enzymes. Using this antibody, they have
reported that immunostaining was observed in normal trachea
but not in normal peripheral lung tissues, supporting our study.
However, in contrast to our results, they reported that the
expression of CYP2A13 protein was not detected in any adeno-
carcinomas (n = 6), squamous carcinomas (n = 3), large cell
carcinomas (n = 3), alveolar carcinomas (n = 3), basaloid carci-
noma (n = 1), or papillary bronchiolar carcinoma (n = 1). The
reason for this discrepancy is not clear, but it may partly dependFukami et al.on differences in the numbers of samples or individual differ-
ences. Another possibility is that differences in the reactivity of
the antibodies used may lead to conflicting results.
In summary, we prepared a specific monoclonal antibody
against CYP2A13. The immunohistochemical analysis using
this antibody demonstrated that, in lung tissues, the expression
of CYP2A13 is localized in epithelial cells in the bronchus. We
first found that the expression of CYP2A13 was markedly
increased in lung non-small cell lung carcinomas. The high
expression might be associated with the tumor development and
progression in non-small cell lung carcinomas.
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